Personalis (PSNL) Competitors $4.83 +0.26 (+5.69%) Closing price 04:00 PM EasternExtended Trading$4.92 +0.09 (+1.86%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PSNL vs. NHC, VRDN, AVAH, AHCO, TDOC, GRAL, PNTG, CDNA, FLGT, and FTREShould you be buying Personalis stock or one of its competitors? The main competitors of Personalis include National HealthCare (NHC), Viridian Therapeutics (VRDN), Aveanna Healthcare (AVAH), AdaptHealth (AHCO), Teladoc Health (TDOC), GRAIL (GRAL), The Pennant Group (PNTG), CareDx (CDNA), Fulgent Genetics (FLGT), and Fortrea (FTRE). These companies are all part of the "healthcare" industry. Personalis vs. Its Competitors National HealthCare Viridian Therapeutics Aveanna Healthcare AdaptHealth Teladoc Health GRAIL The Pennant Group CareDx Fulgent Genetics Fortrea National HealthCare (NYSE:NHC) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment. Do analysts rate NHC or PSNL? Personalis has a consensus target price of $7.42, suggesting a potential upside of 53.55%. Given Personalis' stronger consensus rating and higher possible upside, analysts plainly believe Personalis is more favorable than National HealthCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score National HealthCare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Personalis 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, NHC or PSNL? National HealthCare has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than National HealthCare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNational HealthCare$1.37B1.22$66.80M$6.7116.22Personalis$84.61M5.06-$81.28M-$1.28-3.77 Which has more risk and volatility, NHC or PSNL? National HealthCare has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Personalis has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Does the media prefer NHC or PSNL? In the previous week, Personalis had 8 more articles in the media than National HealthCare. MarketBeat recorded 12 mentions for Personalis and 4 mentions for National HealthCare. National HealthCare's average media sentiment score of 0.47 beat Personalis' score of -0.07 indicating that National HealthCare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National HealthCare 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Personalis 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of NHC or PSNL? 56.4% of National HealthCare shares are owned by institutional investors. Comparatively, 61.9% of Personalis shares are owned by institutional investors. 15.0% of National HealthCare shares are owned by insiders. Comparatively, 3.8% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is NHC or PSNL more profitable? National HealthCare has a net margin of 10.03% compared to Personalis' net margin of -113.70%. National HealthCare's return on equity of 6.87% beat Personalis' return on equity.Company Net Margins Return on Equity Return on Assets National HealthCare10.03% 6.87% 4.68% Personalis -113.70%-47.57%-35.05% SummaryNational HealthCare beats Personalis on 9 of the 16 factors compared between the two stocks. Get Personalis News Delivered to You Automatically Sign up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSNL vs. The Competition Export to ExcelMetricPersonalisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$405.25M$3.97B$5.55B$9.83BDividend YieldN/A1.23%4.62%4.11%P/E Ratio-3.778.8821.9425.46Price / Sales5.0613.44460.58105.19Price / CashN/A6.8737.7558.93Price / Book2.255.188.476.06Net Income-$81.28M-$109.62M$3.26B$265.11M7 Day Performance9.52%12.58%3.56%2.90%1 Month Performance-24.18%15.48%5.97%3.99%1 Year Performance3.65%36.36%42.70%26.92% Personalis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSNLPersonalis3.8033 of 5 stars$4.83+5.7%$7.42+53.6%+6.0%$405.25M$84.61M-3.77400NHCNational HealthCareN/A$103.43+3.0%N/A-14.1%$1.60B$1.37B12.9612,400Dividend AnnouncementVRDNViridian Therapeutics1.6503 of 5 stars$16.89+2.9%$37.00+119.1%+17.5%$1.34B$300K0.0050Earnings ReportAnalyst RevisionAVAHAveanna Healthcare1.6391 of 5 stars$6.83+11.2%$6.10-10.7%+56.0%$1.28B$2.02B23.6133,500News CoverageAnalyst UpgradeAHCOAdaptHealth4.058 of 5 stars$9.33+1.5%$13.40+43.6%+1.4%$1.24B$3.26B17.6710,500Gap DownTDOCTeladoc Health2.895 of 5 stars$6.79-2.5%$9.76+43.9%+0.0%$1.23B$2.57B-5.705,500GRALGRAIL0.9849 of 5 stars$32.69-0.4%$31.50-3.6%+118.6%$1.18B$125.60M0.001,360News CoverageEarnings ReportGap DownPNTGThe Pennant Group3.4728 of 5 stars$26.15+0.6%$33.80+29.3%-9.5%$898.61M$695.24M31.717,000News CoverageCDNACareDx4.1697 of 5 stars$11.77-1.7%$27.67+135.1%-53.7%$637.13M$333.79M11.73740Earnings ReportFLGTFulgent Genetics3.7537 of 5 stars$20.61+1.2%$25.33+22.9%-11.9%$623.20M$283.47M0.001,313FTREFortrea3.8334 of 5 stars$6.39-2.9%$14.00+119.1%-63.5%$597.46M$2.70B-0.5615,500Earnings ReportInsider TradeAnalyst Revision Related Companies and Tools Related Companies NHC Competitors VRDN Competitors AVAH Competitors AHCO Competitors TDOC Competitors GRAL Competitors PNTG Competitors CDNA Competitors FLGT Competitors FTRE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PSNL) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Personalis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access